Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -41.20% is 75% above its 2-year average of -161.84%, near the high end of its 2-year range (-343.90%–-34.23%).
As of the fiscal period ended Tuesday, June 30, 2026. 70.52% above its 12-month average of -139.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.20%.
RETURN ON EQUITY (ROE)
-41.20%
RETURN ON EQUITY (ROE) AVG TTM
-139.78%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+70.52%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 341 covered companies
CURRENT VS SECTOR MEDIAN
-41.34%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$734.10M
Return on Equity (ROE)
-41.20%
TTM Avg
-139.78%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$719.64M
Return on Equity (ROE)
N/A
TTM Avg
-222.26%
3Y Avg
276.12%
5Y Avg
157.82%
Market Cap
$749.55M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
Market Cap
$709.33M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$767.46M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$698.60M
Return on Equity (ROE)
-113.05%
TTM Avg
-95.98%
3Y Avg
-72.88%
5Y Avg
-73.85%
Market Cap
$774.32M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$775.72M
Return on Equity (ROE)
-35.07%
TTM Avg
-26.66%
3Y Avg
-24.19%
5Y Avg
-5.48%
Market Cap
$776.24M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | -41.20% | -139.78% | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | -222.26% | 276.12% | 157.82% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -70.19% | -78.37% | -123.45% | -79.18% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 15.36% | 25.54% | 15.72% | 18.75% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -22.36% | -60.32% | -42.71% | -132.49% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -113.05% | -95.98% | -72.88% | -73.85% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -40.21% | -52.14% | -52.14% | -52.14% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -35.07% | -26.66% | -24.19% | -5.48% |
| Geron Corporation (GERN)vs › | $776.24M | -31.97% | -50.13% | -87.97% | -79.93% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -108.93% | -72.41% | -64.95% | -55.74% |
ROE
-41.2%
ROA
-38.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -41.20% |
| 2026-03-31 | -34.23% |
| 2025-06-30 | -343.90% |
| 2025-03-31 | -189.11% |
| 2024-12-31 | -121.56% |
| 2023-12-31 | -241.07% |
